Evidence map›Paper›PMID 22740407›Full record

ArticleJournal of virology2012

CD8+ T cells use TRAIL to restrict West Nile virus pathogenesis by controlling infection in neurons.

Bimmi Shrestha, Amelia K Pinto, Sharone Green, Irene Bosch, Michael S Diamond

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05568953 (An Experimental Medicine Decipher of a Minimum Correlate of Cellular Immunity), which is not on this map. Cited by 50 papers.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
9.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05568953 phase2unknown statusnot on this mapstarted 2022, after this paper: background citation

An Experimental Medicine Decipher of a Minimum Correlate of Cellular Immunity

TypeinterventionalSponsorSingapore General HospitalRan2022 to 2025Enrolled70ConditionsInfectious Disease, Yellow Fever, Japanese Encephalitis, Viral InfectionArmsStamaril, Imojev, Ixiaro
3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 72 citations in OpenAlex.

  1. Article
  2. Modes of action of a small molecule antiviral compound targeting yellow fever virus NS4B protein.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  3. Review
  4. Article
  5. Antigen non-specific CD8bioRxiv : the preprint server for biology · 2024
    Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. The role of antiviral CD8Current opinion in neurobiology · 2022
    Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. TRAILshort Protects against CD4 T Cell Death during Acute HIV Infection.Journal of immunology (Baltimore, Md. : 1950) · 2019
    Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Bimmi ShresthaDepartments of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
Amelia K Pinto
Sharone Green
Irene Bosch
Michael S Diamond
Washington University in St. Louis · USMassachusetts Institute of Technology · USUniversity of Massachusetts Chan Medical School · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Previous studies of mice have demonstrated that an orchestrated sequence of innate and adaptive immune responses is required to control West Nile virus (WNV) infection in peripheral and central nervous system (CNS) tissues. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL; also known as CD253) has been reported to inhibit infection with dengue virus, a closely related flavivirus, in cell culture. To determine the physiological function of TRAIL in the context of flavivirus infection, we compared the pathogenesis of WNV in wild-type and TRAIL(-/-) mice. Mice lacking TRAIL showed increased vulnerability and death after subcutaneous WNV infection. Although no difference in viral burden was detected in peripheral tissues, greater viral infection was detected in the brain and spinal cord at late times after infection, and this was associated with delayed viral clearance in the few surviving TRAIL(-/-) mice. While priming of adaptive B and T cell responses and trafficking of immune and antigen-specific cells to the brain were undistinguishable from those in normal mice, in TRAIL(-/-) mice, CD8(+) T cells showed qualitative defects in the ability to clear WNV infection. Adoptive transfer of WNV-primed wild-type but not TRAIL(-/-) CD8(+) T cells to recipient CD8(-/-) mice efficiently limited infection in the brain and spinal cord, and analogous results were obtained when wild-type or TRAIL(-/-) CD8(+) T cells were added to WNV-infected primary cortical neuron cultures ex vivo. Collectively, our results suggest that TRAIL produced by CD8(+) T cells contributes to disease resolution by helping to clear WNV infection from neurons in the central nervous system.

Indexed as

Adoptive TransferAnimalsAntibodies, ViralBrainCD8-Positive T-LymphocytesHumansMiceMice, Inbred C57BLMice, KnockoutNeuronsSpinal CordTNF-Related Apoptosis-Inducing LigandViral LoadWest Nile FeverWest Nile virusAntibodies, ViralTNF-Related Apoptosis-Inducing Ligand

Identifiers

PMID22740407
PMCPMC3416144
OpenAlexW2037466974

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.